Compugen Ltd.
Compugen Ltd. company was founded in 1993 and is based in Tel Aviv, Israel. Compugen Ltd. (Compugen) is engaged in drug and diagnostic product candidate discovery and the commercialization of such candidates through early-stage licensing and co-development agreements. The Company’s business is focused on developing and using predictive computer-based discovery platforms to discover therapeutic drug candidates and diagnostic biomarker candidates. The Company uses experimental biological processes to validate product candidates discovered by its predictive platforms. Its initial discovery platforms focused mainly on cancer, cardiovascular and immune-related diseases. In July 2008, Compugen announced results from an in vivo study of CGEN-25007, a peptide antagonist of the gp96 protein. The data indicate that CGEN-25007 has immunosuppressive effects and therapeutic potential for the treatment of various inflammatory diseases and other immune related pathologies.
Contact Details
Office Address
Compugen Ltd.
72 Pinchas Rosen Street, Tel Aviv, Israel 69512
Phone: +972-3-765-8585
Fax: +972-3-765-8555
Executives
Co-Chief Exec. Officer
Mr. Martin Gerstel
VP of R&D
Dr. Anat Cohen-Dayag